ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Strategy for Eliminating Passenger Leukocytes in Human Renal Allografts, A

L. Brasile, P. Glowacki, N. Henry, B. Stubenitsky

Breonics, Inc., Albany
University Medical Center, Utrecht, Netherlands

Meeting: 2013 American Transplant Congress

Abstract number: A643

Transplantation is unique immunologically due to both donor and recipient antigen presenting cells being present at reperfusion. Dendritic cells (DC) are a potent type of professional antigen presenting cells. As part of their normal immune surveillance, DC are trapped within the renal parenchyma at the time of organ procurement. Upon reimplantation, the DC migrate out of the allograft into secondary lymphatics where recipient immune cells encounter the foreign antigens on the passenger leukocytes via direct antigen presentation and from then on there is the up-hill battle to prevent rejection. If strategies can be developed that minimizes this initial allorecognition, there could be a positive impact on outcomes. Using an acellular, near-normothermic perfusion technology, called Exsanguinous Metabolic Support (EMS) we evaluated the feasibility of removing the DC from human kidneys. Methods – Human allografts deemed to be non-transplantable according to standard criteria were procured for this study. The human kidneys were received on ice, flushed with EMS solution (32°C) and placed on perfusion. An initial biopsy was taken before and again after the period of EMS perfusion (either 24 or 48 hours). Frozen sections were made from representative sections of the kidneys. The number and location of the DC within the kidneys were determined using an indirect immunofluorescence assay with CD209 (DC-sign) antibody and secondary antibody of Alexafluor488, along fluoroshield plus DAPI. Results – There was a significant reduction in the number of resident DC following either 24 or 48 hours of EMS perfusion.

Elimination of DC+ in Human Kidneys during EMS Perfusion∗†
  Pre Post
Kidney DC+ ∗ 12.78±9.1 6.06±3.67
Perfusate DC† 0 1.02 x10^6
∗ Kidney DC+: mean/60 field †Conc. of DC is circulating perfusate

This finding is mirrored by the increasing concentration of DC found in the circulating EMS solution after perfusion. Conclusion – This study demonstrates the initial feasibility of depleting renal allografts of passenger leukocytes pretransplant during a period of warm acellular perfusion. We are currently evaluating non-toxic adjunct techniques for further enhancement of depletion.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Brasile L, Glowacki P, Henry N, Stubenitsky B. Strategy for Eliminating Passenger Leukocytes in Human Renal Allografts, A [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/strategy-for-eliminating-passenger-leukocytes-in-human-renal-allografts-a/. Accessed May 17, 2025.

« Back to 2013 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences